- Home
- NCPL vs GLTO Comparison
NCPL vs GLTO Comparison
Compare NCPL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- GLTO
- Stock Information
- Founded
- NCPL 1984
- GLTO 2011
- Country
- NCPL United States
- GLTO Denmark
- Employees
- NCPL N/A
- GLTO N/A
- Industry
- NCPL Investment Managers
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- GLTO Health Care
- Exchange
- NCPL Nasdaq
- GLTO Nasdaq
- Market Cap
- NCPL 4.3M
- GLTO 4.0M
- IPO Year
- NCPL N/A
- GLTO 2020
- Fundamental
- Price
- NCPL $2.67
- GLTO $3.07
- Analyst Decision
- NCPL
- GLTO Buy
- Analyst Count
- NCPL 0
- GLTO 1
- Target Price
- NCPL N/A
- GLTO $10.00
- AVG Volume (30 Days)
- NCPL 153.1K
- GLTO 82.7K
- Earning Date
- NCPL 07-28-2025
- GLTO 05-08-2025
- Dividend Yield
- NCPL N/A
- GLTO N/A
- EPS Growth
- NCPL N/A
- GLTO N/A
- EPS
- NCPL N/A
- GLTO N/A
- Revenue
- NCPL $812,612.00
- GLTO N/A
- Revenue This Year
- NCPL N/A
- GLTO N/A
- Revenue Next Year
- NCPL $101.16
- GLTO N/A
- P/E Ratio
- NCPL N/A
- GLTO N/A
- Revenue Growth
- NCPL N/A
- GLTO N/A
- 52 Week Low
- NCPL $1.41
- GLTO $2.01
- 52 Week High
- NCPL $11.90
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- NCPL 75.93
- GLTO 53.39
- Support Level
- NCPL $1.75
- GLTO $2.92
- Resistance Level
- NCPL $2.19
- GLTO $3.38
- Average True Range (ATR)
- NCPL 0.18
- GLTO 0.25
- MACD
- NCPL 0.04
- GLTO 0.04
- Stochastic Oscillator
- NCPL 89.01
- GLTO 57.53
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.